Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Neonatal abstinence syndrome

Lauren M Jansson, MD
Section Editor
Joseph A Garcia-Prats, MD
Deputy Editor
Melanie S Kim, MD


A newborn infant born to a mother with an opioid use disorder or using/taking other substances is at risk for drug withdrawal, commonly referred to as neonatal abstinence syndrome (NAS). NAS is a variable, complex, and incompletely understood spectrum of signs of neonatal behavioral dysregulation.

Although most commonly associated with opioid exposure, other substances have been associated with an abstinence syndrome, including nicotine. Additionally, other substances, such as cigarettes, benzodiazepines, and selective serotonin reuptake inhibitors (SSRIs), can potentiate the severity of NAS.

The clinical manifestations, diagnosis, and management of NAS will be reviewed here. Opioid use during pregnancy and neonatal exposure to other drugs of substance use disorder are reviewed separately. (See "Infants of mothers with substance use disorder" and "Substance misuse in pregnant women" and "Methadone substitution treatment of opioid use disorder during pregnancy".)


The term opioid refers to natural and synthetic substances with morphine-like activities that activate mu-opioid receptors in the central nervous system and gastrointestinal tract. Opiate refers to a subclass of opioids consisting of alkaloid compounds extracted or derived from opium that include morphine, codeine, and semisynthetic derivatives such as heroin, methadone, fentanyl, hydromorphone, and buprenorphine. (See "Opioid use disorder: Epidemiology, pharmacology, clinical manifestations, course, screening, assessment, and diagnosis".)

Pregnant women with substance use disorders who are dependent on opioids are generally maintained on methadone, which provides multiple benefits including improved prenatal care, reduced fetal mortality, and improved fetal growth [1]. Buprenorphine has become an acceptable alternate opioid during pregnancy with potential benefit for reduced severity of NAS [2]. The management of pregnant women dependent on opioids is discussed separately. (See "Substance misuse in pregnant women" and "Methadone substitution treatment of opioid use disorder during pregnancy" and "Buprenorphine substitution therapy in pregnancy".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Apr 2017. | This topic last updated: May 17, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Kandall SR, Albin S, Gartner LM, et al. The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev 1977; 1:159.
  2. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363:2320.
  3. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008. MMWR Morb Mortal Wkly Rep 2011; 60:1487.
  4. Patrick SW, Schumacher RE, Benneyworth BD, et al. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012; 307:1934.
  5. Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol 2015; 35:650.
  6. Ko JY, Patrick SW, Tong VT, et al. Incidence of Neonatal Abstinence Syndrome - 28 States, 1999-2013. MMWR Morb Mortal Wkly Rep 2016; 65:799.
  7. Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med 2015; 372:2118.
  8. Ostrea EM Jr, Brady MJ, Parks PM, et al. Drug screening of meconium in infants of drug-dependent mothers: an alternative to urine testing. J Pediatr 1989; 115:474.
  9. Doberczak TM, Kandall SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr 1991; 118:933.
  10. Alroomi LG, Davidson J, Evans TJ, et al. Maternal narcotic abuse and the newborn. Arch Dis Child 1988; 63:81.
  11. Lam SK, To WK, Duthie SJ, Ma HK. Narcotic addiction in pregnancy with adverse maternal and perinatal outcome. Aust N Z J Obstet Gynaecol 1992; 32:216.
  12. Fricker HS, Segal S. Narcotic addiction, pregnancy, and the newborn. Am J Dis Child 1978; 132:360.
  13. Maas U, Kattner E, Weingart-Jesse B, et al. Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. J Perinat Med 1990; 18:111.
  14. Patrick SW, Dudley J, Martin PR, et al. Prescription opioid epidemic and infant outcomes. Pediatrics 2015; 135:842.
  15. Seligman NS, Almario CV, Hayes EJ, et al. Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. J Pediatr 2010; 157:428.
  16. Kocherlakota P. Neonatal abstinence syndrome. Pediatrics 2014; 134:e547.
  17. Wachman EM, Hayes MJ, Brown MS, et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 2013; 309:1821.
  18. Mague SD, Blendy JA. OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend 2010; 108:172.
  19. Wachman EM, Hayes MJ, Lester BM, et al. Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome. J Pediatr 2014; 165:472.
  20. Jansson LM, Velez M. Neonatal abstinence syndrome. Curr Opin Pediatr 2012; 24:252.
  21. Hudak ML, Tan RC, COMMITTEE ON DRUGS, et al. Neonatal drug withdrawal. Pediatrics 2012; 129:e540.
  22. Bio LL, Siu A, Poon CY. Update on the pharmacologic management of neonatal abstinence syndrome. J Perinatol 2011; 31:692.
  23. Liu AJ, Jones MP, Murray H, et al. Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. Aust N Z J Obstet Gynaecol 2010; 50:253.
  24. Zelson C, Rubio E, Wasserman E. Neonatal narcotic addiction: 10 year observation. Pediatrics 1971; 48:178.
  25. Kandall SR, Gartner LM. Late presentation of drug withdrawal symptoms in newborns. Am J Dis Child 1974; 127:58.
  26. Herzlinger RA, Kandall SR, Vaughan HG Jr. Neonatal seizures associated with narcotic withdrawal. J Pediatr 1977; 91:638.
  27. Feng Y, He X, Yang Y, et al. Current research on opioid receptor function. Curr Drug Targets 2012; 13:230.
  28. van Baar AL, Fleury P, Soepatmi S, et al. Neonatal behavior after drug dependent pregnancy. Arch Dis Child 1989; 64:235.
  29. Pinto F, Torrioli MG, Casella G, et al. Sleep in babies born to chronically heroin addicted mothers. A follow up study. Drug Alcohol Depend 1988; 21:43.
  30. Liu AJ, Sithamparanathan S, Jones MP, et al. Growth restriction in pregnancies of opioid-dependent mothers. Arch Dis Child Fetal Neonatal Ed 2010; 95:F258.
  31. Dysart K, Hsieh HC, Kaltenbach K, Greenspan JS. Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome. J Perinat Med 2007; 35:344.
  32. Kraft WK, Stover MW, Davis JM. Neonatal abstinence syndrome: Pharmacologic strategies for the mother and infant. Semin Perinatol 2016; 40:203.
  33. Ostrea EM Jr, Knapp DK, Tannenbaum L, et al. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J Pediatr 2001; 138:344.
  34. Montgomery D, Plate C, Alder SC, et al. Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium. J Perinatol 2006; 26:11.
  35. United States Drug Testing Laboratory (www.usdtl.com) (Accessed on January 02, 2014).
  36. Wiles JR, Isemann B, Ward LP, et al. Current management of neonatal abstinence syndrome secondary to intrauterine opioid exposure. J Pediatr 2014; 165:440.
  37. Velez M, Jansson LM. The Opioid dependent mother and newborn dyad: non-pharmacologic care. J Addict Med 2008; 2:113.
  38. Lipsitz PJ. A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. Clin Pediatr (Phila) 1975; 14:592.
  39. Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975; 2:141.
  40. Zahorodny W, Rom C, Whitney W, et al. The neonatal withdrawal inventory: a simplified score of newborn withdrawal. J Dev Behav Pediatr 1998; 19:89.
  41. Hall ES, Wexelblatt SL, Crowley M, et al. A multicenter cohort study of treatments and hospital outcomes in neonatal abstinence syndrome. Pediatrics 2014; 134:e527.
  42. Hall ES, Wexelblatt SL, Crowley M, et al. Implementation of a Neonatal Abstinence Syndrome Weaning Protocol: A Multicenter Cohort Study. Pediatrics 2015; 136:e803.
  43. Heil SH, Gaalema DE, Johnston AM, et al. Infant pupillary response to methadone administration during treatment for neonatal abstinence syndrome: a feasibility study. Drug Alcohol Depend 2012; 126:268.
  44. Oji-Mmuo CN, Michael EJ, McLatchy J, et al. Skin conductance at baseline and postheel lance reflects sympathetic activation in neonatal opiate withdrawal. Acta Paediatr 2016; 105:e99.
  45. O'Brien C, Hunt R, Jeffery HE. Measurement of movement is an objective method to assist in assessment of opiate withdrawal in newborns. Arch Dis Child Fetal Neonatal Ed 2004; 89:F305.
  46. Howard MB, Schiff DM, Penwill N, et al. Impact of Parental Presence at Infants' Bedside on Neonatal Abstinence Syndrome. Hosp Pediatr 2017; 7:63.
  47. Academy of Breastfeeding Medicine Protocol Committee, Jansson LM. ABM clinical protocol #21: Guidelines for breastfeeding and the drug-dependent woman. Breastfeed Med 2009; 4:225.
  48. Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics 2013; 132:e796.
  49. Jansson LM, Choo R, Velez ML, et al. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics 2008; 121:106.
  50. Abdel-Latif ME, Pinner J, Clews S, et al. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics 2006; 117:e1163.
  51. Isemann B, Meinzen-Derr J, Akinbi H. Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome. J Perinatol 2011; 31:25.
  52. Welle-Strand GK, Skurtveit S, Jansson LM, et al. Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. Acta Paediatr 2013; 102:1060.
  53. Ilett KF, Hackett LP, Gower S, et al. Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment. Breastfeed Med 2012; 7:269.
  54. Hall ES, Isemann BT, Wexelblatt SL, et al. A Cohort Comparison of Buprenorphine versus Methadone Treatment for Neonatal Abstinence Syndrome. J Pediatr 2016; 170:39.
  55. Kraft WK, Adeniyi-Jones SC, Chervoneva I, et al. Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome. N Engl J Med 2017.
  56. Forcelli PA, Janssen MJ, Stamps LA, et al. Therapeutic strategies to avoid long-term adverse outcomes of neonatal antiepileptic drug exposure. Epilepsia 2010; 51 Suppl 3:18.
  57. Forcelli PA, Kim J, Kondratyev A, Gale K. Pattern of antiepileptic drug-induced cell death in limbic regions of the neonatal rat brain. Epilepsia 2011; 52:e207.
  58. Forcelli PA, Kozlowski R, Snyder C, et al. Effects of neonatal antiepileptic drug exposure on cognitive, emotional, and motor function in adult rats. J Pharmacol Exp Ther 2012; 340:558.
  59. Agthe AG, Kim GR, Mathias KB, et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics 2009; 123:e849.
  60. Johnson K, Gerada C, Greenough A. Treatment of neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed 2003; 88:F2.
  61. Blume HK, Garrison MM, Christakis DA. Neonatal seizures: treatment and treatment variability in 31 United States pediatric hospitals. J Child Neurol 2009; 24:148.
  62. Surran B, Visintainer P, Chamberlain S, et al. Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. J Perinatol 2013; 33:954.
  63. Osborn DA, Jeffery HE, Cole MJ. Sedatives for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2010; :CD002053.
  64. Bada HS, Sithisarn T, Gibson J, et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics 2015; 135:e383.
  65. Streetz VN, Gildon BL, Thompson DF. Role of Clonidine in Neonatal Abstinence Syndrome: A Systematic Review. Ann Pharmacother 2016; 50:301.
  66. Gibbs J, Newson T, Williams J, Davidson DC. Naloxone hazard in infant of opioid abuser. Lancet 1989; 2:159.
  67. Bunikowski R, Grimmer I, Heiser A, et al. Neurodevelopmental outcome after prenatal exposure to opiates. Eur J Pediatr 1998; 157:724.
  68. van Baar AL, Soepatmi S, Gunning WB, Akkerhuis GW. Development after prenatal exposure to cocaine, heroin and methadone. Acta Paediatr Suppl 1994; 404:40.
  69. Uebel H, Wright IM, Burns L, et al. Reasons for Rehospitalization in Children Who Had Neonatal Abstinence Syndrome. Pediatrics 2015; 136:e811.
  70. Nygaard E, Moe V, Slinning K, Walhovd KB. Longitudinal cognitive development of children born to mothers with opioid and polysubstance use. Pediatr Res 2015; 78:330.
  71. Oei JL, Melhuish E, Uebel H, et al. Neonatal Abstinence Syndrome and High School Performance. Pediatrics 2017; 139.
  72. Baldacchino A, Arbuckle K, Petrie DJ, McCowan C. Neurobehavioral consequences of chronic intrauterine opioid exposure in infants and preschool children: a systematic review and meta-analysis. BMC Psychiatry 2014; 14:104.